SecBot SecBot
PRESS-RELEASE ·Filed Apr 21, 2026

RVMD

Revolution Medicines, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The 58% ORR in first-line PDAC is well above historical chemo benchmarks (~30-35%), suggesting potential for accelerated approval. Monitor upcoming Phase 3 readouts and any FDA breakthrough designation decisions. Despite recent insider selling, the clinical signal is strong enough to justify near-term upside.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$141.50
T+0 close · Apr 21, 2026 · via day close
Latest settled
+31.56%
T+60 · $186.16
Vs SPY
+26.78%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 22 $141.50entry
  2. T+1 · 7mo ago −4.96%α −4.57% · $134.48
  3. T+5 · 7mo ago −0.49%α −0.55% · $140.80
  4. T+20 · 6mo ago +4.10%α +0.93% · $147.30
  5. T+60 · 4mo ago +31.56%α +26.78% · $186.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines announced updated Phase 1/2 data for daraxonrasib in previously untreated metastatic pancreatic cancer, showing a 58% confirmed ORR in combination with chemotherapy and 47% in monotherapy, with manageable safety profiles. These results support ongoing Phase 3 trials in frontline PDAC, a high-unmet need indication with ~3% five-year survival.

Key Facts

  • Daraxonrasib + GnP combination showed 58% confirmed ORR (95% CI: 41, 73) in 40 patients with metastatic PDAC
  • Monotherapy arm showed 47% ORR (95% CI: 31, 64), including one complete response
  • No Grade 5 treatment-related adverse events reported in either cohort
  • Phase 3 RASolute 303 trial ongoing in first-line PDAC; RASolute 302 recently met PFS and OS endpoints
  • Pancreatic cancer has ~3% five-year survival rate; >90% of cases harbor RAS mutations

Financial Impact

High potential value creation if Phase 3 trials confirm efficacy, given lack of effective frontline therapies in PDAC and $29B market cap

revenueepsmarketCap

Risk Factors

  • Early-phase data with immature PFS/OS; later-stage results may not confirm benefit
  • Competitive landscape could shift with other RAS inhibitors in development
  • High market cap reflects significant expectations; any clinical setback could trigger sharp downside

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3278575

US Market Status

Market Closed · Opens in 8h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026